Treating Advanced-Stage Lung Cancer with TKIs

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)

Clinical Pearls

• Many patients have comorbid diseases and are very sick when they are diagnosed with lung cancer
• TKIs are oral, do not require an IV and they do not have grade 3 and 4 life-threatening toxicities
• Sick patients who have lung cancer should have molecular testing to see if they are eligible to use TKIs